Regionally specific effects of haloperidol and clozapine on dopamine reuptake in the striatum
Section snippets
Acknowledgements
This research was supported by the F.M. Kirby Foundation. The authors thank Dr. T.I. Lidsky for providing helpful comments concerning this research.
References (24)
- et al.
Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics
Eur. J. Pharmacol.
(1993) - et al.
Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA
Brain Res.
(1991) - et al.
Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake
Neurosci. Lett.
(1994) - et al.
Increased dopamine clearance in the non-lesioned striatum of rhesus monkeys with unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) striatal lesions
Neurosci. Lett.
(1995) - et al.
Dopamine D2 and D3 receptor preferring antagonists differentially affect striatal dopamine release and metabolism in conscious rats
Eur. J. Pharmacol.
(1994) - et al.
Anti-glutamatergic effects of clozapine
Neurosci. Lett.
(1993) - et al.
Clozapine decreases enkephalin mRNA in rat striatum
Neurosci. Lett.
(1992) - et al.
Haloperidol-induced morphological changes in striatum are associated with glutamate synapses
Brain Res.
(1994) - et al.
Loss of striatal cholinergic neurons as a basis for tardive and l-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia
Biol. Psychiatry
(1993) - et al.
Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats
Brain Res.
(1995)
Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and the caudate-putamen in rats
Neuroscience
Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum
J. Pharmacol. Exp. Ther.
Cited by (29)
The influence of dopamine autoreceptors on temperament and addiction risk
2023, Neuroscience and Biobehavioral ReviewsStriatal dopamine neurotransmission: Regulation of release and uptake
2016, Basal GangliaCitation Excerpt :Activation of several GPCRs can also regulate DAT function [388,389]. Studies using acute administration of agonists and antagonists of the D2 receptor have established a positive regulation of DAT activity and surface expression by D2 DA autoreceptor activation in vivo and in vitro [410–416]. D2 receptor-dependent upregulation of DAT activity may involve G-proteins, ERK1/2 and PKA [411,415,417], with inhibition of ERK1/2 leading to a decrease in DAT function and its cell-surface localization [418].
Regulation of Extracellular Dopamine: Release and Uptake
2016, Handbook of Behavioral NeuroscienceCitation Excerpt :Activation of several G-protein-coupled receptors can also regulate DAT function (Gulley and Zahniser, 2003; Schmitt and Reith, 2010). Most studies using acute administration of agonists and antagonists of the D2 receptor have established a positive regulation of DAT activity and surface expression by D2 autoreceptors in vivo and in vitro (Batchelor and Schenk, 1998; Cass and Gerhardt, 1994; Mayfield and Zahniser, 2001; Meiergerd et al., 1993; Rothblat and Schneider, 1997; Wieczorek and Kruk, 1994; Wu et al., 2002). D2-receptor-dependent upregulation of DAT activity may involve G-proteins, ERK1/2, and PKA (Batchelor and Schenk, 1998; Bolan et al., 2007; Mayfield and Zahniser, 2001), with inhibition of ERK1/2 leading to a decrease in DAT function and its cell-surface localization (Moron et al., 2003).
Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors
2012, Basal GangliaCitation Excerpt :There are multiple pathways or mechanisms at different time scales to achieve this. Activation of dopamine autoreceptors can decrease release by inhibiting dopamine synthesis and enhancing dopamine reuptake by the dopamine transporter as well as regulating vesicular monoamine transporter (VMAT2) expression [4,14,15]. These are slow processes that may last for minutes to hours.
Regulation of Extracellular Dopamine: Release and Reuptake
2010, Handbook of Behavioral NeuroscienceCitation Excerpt :However, even in these regions, pharmacological inhibition of DAT strongly slows the clearance of released dopamine (Mundorf et al., 2001). In vivo studies (Cass and Gerhardt, 1994; Rothblat and Schneider, 1997) show that D2 antagonists slow the clearance of exogenously applied dopamine. Moreover, D2 antagonists decrease the rate of elimination of endogenous dopamine released in vivo by electrical stimulation (Benoit-Marand et al., 2001; Wu et al., 2002).
Neural basis of psychosis-related behaviour in the infection model of schizophrenia
2009, Behavioural Brain Research